nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2-metastatic breast cancer
dc.contributor.author | Hamilton, E.P. | |
dc.contributor.author | Cortes, J. | |
dc.contributor.author | Ozyilkan, O. | |
dc.contributor.author | Chen, S-C. | |
dc.contributor.author | Petrakova, K. | |
dc.contributor.author | Manikhas, A. | |
dc.contributor.author | Jerusalem, G. | |
dc.contributor.author | Hegg, R. | |
dc.contributor.author | Huober, J. | |
dc.contributor.author | Chapman, S.C. | |
dc.contributor.author | Yang, Z. | |
dc.contributor.author | Chen, Y. | |
dc.contributor.author | Johnston, E.L. | |
dc.contributor.author | Martin, M. | |
dc.contributor.orcID | 0000-0001-8825-4918 | en_US |
dc.contributor.researcherID | AAD-2817-2021 | en_US |
dc.date.accessioned | 2021-04-28T06:54:38Z | |
dc.date.available | 2021-04-28T06:54:38Z | |
dc.date.issued | 2020 | |
dc.description.sponsorship | European Soc Med Oncol | en_US |
dc.identifier.endpage | S348 | en_US |
dc.identifier.issn | 0923-7534 | en_US |
dc.identifier.startpage | S348 | en_US |
dc.identifier.uri | https://www.annalsofoncology.org/article/S0923-7534(20)40371-0/pdf | |
dc.identifier.uri | http://hdl.handle.net/11727/5788 | |
dc.identifier.volume | 31 | en_US |
dc.identifier.wos | 000573469100273 | en_US |
dc.language.iso | eng | en_US |
dc.relation.isversionof | 10.1016/j.annonc.2020.08.375 | en_US |
dc.relation.journal | ANNALS OF ONCOLOGY | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.title | nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2-metastatic breast cancer | en_US |
dc.type | conferenceObject | en_US |
Files
Original bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- PIIS0923753420403710.pdf
- Size:
- 143.01 KB
- Format:
- Adobe Portable Document Format
- Description:
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: